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Background: We demonstrated that intramyocardial bone marrow cell (BMC) injection improved myocardial perfusion and anginal symptoms in 
patients with refractory angina pectoris (Ramshorst ea. JAMA 2009). Since some patients experienced recurrent anginal complaints, this study was 
designed to evaluate the efficacy of a repeat intramyocardial BMC injection. 
methods: Patients with refractory angina pectoris, who improved after previous intramyocardial BMC injection and experienced recurrent anginal 
complaints with documented ischemia, were enrolled. Using the NOGA-system, 100x10^6 autologous BMC were intramyocardially injected. Single-
photon emission computed tomography was done at baseline and after 3 months to assess myocardial perfusion. Anginal symptoms and quality of 
life (QoL) were evaluated at baseline, 3 and 6 months follow-up. 
results: In total, 23 patients (17 male, 69±9 years) were injected 4.6±2.5 years after their first BMC injection. After repeat injection, summed 
stress score significantly improved similar to the first injection (resp. P<0.001 and P=0.06). Patients reported a decrease of anginal episodes equal 
to the first injection (resp. P=.02 and P=.25). Also QoL improved (P=.02). However, improvement was more pronounced after the first injection 
(P<.01). 
conclusion: Repeat intramyocardial BMC injection improves myocardial perfusion and anginal symptoms in previously responding patients with 
recurrent anginal complaints and documented myocardial ischemia.
 
